Pacemaker Needs Rise After TAVI Procedures in Spain
The incidence of implantation of a permanent pacemaker immediately after transcatheter aortic valve implantation (TAVI) increased significantly over a period of 6 years in Spain, and this rising trend remained independent of sex, age, comorbidities, or procedural volumes at the hospitals.
METHODOLOGY:
Researchers in Spain conducted a retrospective observational study using data from a national hospital discharge database to analyse the incidence of pacemaker implantation immediately after TAVI.
They analysed 20,826 episodes of TAVI performed between 2017 and 2022 in patients older than 60 years without a prior pacemaker.
The primary outcome was the implantation of a permanent pacemaker during the same hospitalisation as the TAVI procedure.
TAKEAWAY:
Overall, 16.8% of patients required the implantation of a pacemaker, with the yearly incidence of implantation increased from 15.2% to 18.2% from 2017 to 2022 (P for trend < .001).
The rising trend in pacemaker implantation was independent of sex, age, or burden of comorbidities and was not significantly influenced by the annual volume of TAVI performed at the hospitals.
IN PRACTICE:
"[The study] findings are clinically relevant and should be considered when selecting patients and optimising the procedure to reduce the need for post-TAVI pacemaker implantation," the authors wrote.
SOURCE:
This study was led by Manuel Carnero-Alcázar, MD, PhD, Hospital Clínico San Carlos, Madrid, Spain. It was published online on June 18, 2025, in Open Heart.
LIMITATIONS:
The dataset used in this study lacked information on procedural characteristics such as depth of implantation and type of valve. The retrospective and observational study design prevented the investigators from determining whether the analysed variables directly increased the pacemaker risk. Pacemaker implantation was captured only during the initial admission to the hospital.
DISCLOSURES:
This study did not receive any specific funding. The authors declared having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
27 minutes ago
- Health Line
Does Medicare Cover Acupuncture for Neuropathy?
Original Medicare only covers acupuncture to treat chronic lower back pain. But some Part C plans might cover acupuncture for treating other pain conditions like neuropathy. Acupuncture, a holistic practice with a history spanning thousands of years, is thought to be effective for treating both acute and chronic pain, including neuropathy or nerve pain. In 2020, the Centers for Medicare & Medicaid Services (CMS) introduced new regulations concerning Medicare's coverage for acupuncture treatments. However, these new regulations do not extend to covering acupuncture for neuropathy treatment. Why does Medicare not pay for acupuncture for neuropathy? Original Medicare (parts A and B) only covers acupuncture when used to treat chronic lower back pain. The plan tends to cover medical care that is medically necessary and proven to be effective. Although neuropathic pain is common, and acupuncture does show some promise in treating it, more research is needed to confirm the treatment's effectiveness in this space. This means Original Medicare may consider acupuncture for neuropathy as experimental or without sufficient evidence for its effectiveness. How do I get Medicare to pay for acupuncture? You aren't likely to get acupuncture for neuropathy covered under Original Medicare. That said, you have the option of signing up for Medicare Advantage (Part C), which is an alternative to Original Medicare. Part C plans are managed by private insurers, and some Part C plans may offer benefits that Original Medicare does not offer. They may approve coverage for acupuncture for indications not covered by Original Medicare, including for neuropathy. Medicare Advantage Open Enrollment Medicare open enrollment occurs each year from October 15 through December 7. During this period, you may join, drop, or switch Original Medicare, Medicare Advantage, or Part D plans. You can find Part C plans available in your area by entering your zip code on Just remember, even if your plan approves coverage, you may need to see an acupuncture provider in your plan's network, depending on the type of plan you have. How many acupuncture visits does Medicare cover? Under Original Medicare, when you get acupuncture for chronic lower back pain, Medicare Part B covers 12 acupuncture sessions within 90 days and up to 20 sessions per year. If you show improvement during treatment, Part B may cover an additional eight sessions. However, this would not apply to acupuncture when needed for treating neuropathy. If you are enrolled in a Part C plan and your plan approves your acupuncture treatment for neuropathy, the number of sessions you can get covered will depend on your plan. How much would acupuncture for neuropathy cost under Medicare? Acupuncture for chronic lower back pain that falls under Part B will be covered once a person meets their annual deductible, which is $257 in 2025. After that, Part B will pay for 80% of the cost. If your Part C plan approves acupuncture for neuropathy, your coinsurance, deductible, and premium will depend on your plan. According to the Centers for Medicaid & Medicare (CMS), the average monthly premium for Part C plans is around $17 in 2025. In addition, to stay enrolled in a Part C plan, you still have to pay the Part B premium. That said, some Part C may cover your Part B premium. Does acupuncture get rid of neuropathy? Acupuncture involves inserting needles into pressure points to stimulate the nervous system, potentially releasing endorphins for natural pain relief and altering pain responses. Research suggests acupuncture could help treat peripheral neuropathy and neuropathic pain, and methods like electroacupuncture show promise in reducing nerve sensitivity and inflammation. Reviews have also found acupuncture beneficial for diabetic peripheral neuropathy, neuropathy from spinal cord injury, and chemotherapy-induced neuropathy, though more research is needed to verify the effectiveness. »Learn more: Acupuncture for Neuropathy Takeaway Acupuncture may be effective in treating both acute and chronic pain, including nerve pain or neuropathy. In 2020, the Centers for Medicare & Medicaid Services (CMS) implemented new rules regarding Medicare's coverage of acupuncture treatments. However, these regulations do not include coverage for acupuncture as a treatment for neuropathy. Currently, Original Medicare solely covers acupuncture for back pain. However, certain Part C plans may offer coverage for acupuncture to treat other conditions, such as neuropathy.
Medscape
an hour ago
- Medscape
CISH-Targeted TILs Show Promise in GI Cancer Trial
This transcript has been edited for clarity. Hello. I'm David Kerr, professor of cancer medicine at University of Oxford. I'd like to talk a little about a phase 1 trial that has just been published in the May edition of Lancet Oncology , a beautiful paper by Emil Lou and colleagues, in which they all looked at an extraordinarily complicated regimen of gene editing and then reinfusing tumor-infiltrating lymphocytes (TILs). This just shows how remarkable modern cancer medicine can be. I'd like to talk a little about the procedures involved, given the route of complexity. Initially, for patients in the phase 1 trial with metastatic advanced gastrointestinal cancer, the first step was to receive a non-myeloablative lymphocyte-depletion chemotherapy. This is cyclophosphamide and fludarabine. This is then followed by high-dose interleukin-2. The process of producing the gene-edited TILs is absolutely fascinating. The gene-editing target, the gene that we wanted to knock down, was a novel, internal immune checkpoint protein gene, CISH , which encoded a cytokine-inducible SH2 domain-containing protein. This is an internal immune checkpoint target and quite an interestingly novel one. That's the target to knock down. The process of building the therapy is completely fascinating. Autologous TILs were generated from tumor biopsy fragments from each individual patient, and samples of the TILs were then cultured with patient-derived lymphoblastic cell lines, ormonocyte-derived dendritic cells loaded with pools of synthetic 25-mer peptides containing tumor-specific mutations that were detected from whole-exome sequencing from the patient's tumor. Think about that for a second. The patients undergo biopsy. The TILs are taken off for culture — more on that later — but they were co-cultured with a source of patient-specific tumor-associated antigens, which were generated by whole-exome sequencing. Then, using 25-mer fragments of what they felt were the key tumor-specific antigens, were plumbed into the patients' own dendritic cells so that these antigens would be presented to at the time of co-culture with a patient, so in TILs. It boggles the mind. The TILs with demonstrated reactivity to the neoantigens in this co-culture experiment were selected and they were then subjected to the CRISPR gene editing in vitro. They knocked down CISH , the target that they were aiming for. Then the edited TILs underwent a rapid expansion protocol. They were cryopreserved, and then via some very sophisticated molecular quality control, infused back into the patients. Goodness gracious — I mean, it's extraordinary when you think about it. It was a phase 1 trial, so dose-escalating the number of cells. It's pretty well tolerated. As you would expect, there was some fatigue and some fever. Nobody died in the back of any of the treatment that was given in that way. In terms of effectiveness, these were patients with advanced disease who had undergone multiple previous lines of treatment. There were no severe cytokine-release syndromes, nothing of grade 3 or worse. No neurotoxicity. Six of 12 patients had stable disease by day 28. Four (33%) had stable disease ongoing at 56 days. One young adult who had microsatellite-unstable and mismatch repair-deficient MSI-high tumors — therefore they've already got an existing high neoantigen load — had a complete response. That was very pleasing. I say, again, this is an extraordinary piece of work, to think about the complexity involved in every step of that process — before the patients' own cells, the autologous cells, were manipulated and reinfused with moderately acceptable toxicity, I would say. It's a phase 1 trial, so you're not really looking for a big efficacy readout, but the one younger patient who had, if you like, a genetic predisposition to responding to immunotherapy anyway, had a complete response. I'd be really interested in what you think about it. Who knows what the cost of that would be in terms of the complexity — I keep using that word, don't I? — of every single step. Modern cancer medicine — don't you love it? Well done to the team for producing this phase 1 trial result. How generalizable it will be remains to be seen, given the multiple different steps that are required. It just shows you how, in my lifetime as a cancer doctor, four decades, remarkable progress has been. I'm very interested in any comments you'd have to make. As always, thanks for listening. For the time being, Medscapers, ahoy, and over and out.
Associated Press
an hour ago
- Associated Press
Mayors, doctor groups sue over Trump's efforts to restrict Obamacare enrollment
WASHINGTON (AP) — New Trump administration rules that give millions of people a shorter timeframe to sign up for the Affordable Care Act's health care coverage are facing a legal challenge from Democratic mayors around the country. The rules, rolled out last month, reverse a Biden-era effort to expand access to the Affordable Care Act's health insurance, commonly called 'Obamacare' or the ACA. The previous Democratic administration expanded the enrollment window for the coverage, which led to record enrollment. The Department of Health and Human Services rolled out a series of new restrictions for Obamacare late last month, just as Congress was weighing a major bill that will decrease enrollment in the health care program that Republican President Donald Trump has scorned for years. As many as 2 million people — nearly 10% — are expected to lose coverage from the health department's new rules. The mayors of Baltimore, Chicago and Columbus, Ohio sued the federal health department on Tuesday over the rules, saying they will result in more uninsured residents and overburden city services. 'Cloaked in the pretense of government efficiency and fraud prevention, the 2025 Rule creates numerous barriers to affordable insurance coverage, negating the purpose of the ACA to extend affordable health coverage to all Americans, and instead increasing the population of underinsured and uninsured Americans,' the filing alleges. Two liberal advocacy groups — Doctors for America and Main Street Alliance — joined in on the complaint. The federal health department announced a series of changes late last month to the ACA. It will shorten the enrollment period for the federal marketplace by a month, limiting it to Nov. 1 to Dec. 15 in 2026. Income verification checks will become more stringent and a $5 fee will be tacked on for some people who automatically re-enroll in a free plan. Insurers will also be able to deny coverage to people who have not paid their premiums on past plans. The rules also bar roughly 100,000 immigrants who were brought to the U.S. as children from signing up for the coverage. HHS said in a statement that the polices 'are temporary measures to immediately tamp down on improper enrollments and the improper flow of federal funds.' The mayors — all Democrats — argue that the polices were introduced without an adequate public comment period on the policies. 'This unlawful rule will force families off their health insurance and raise costs on millions of Americans. This does nothing to help people and instead harms Americans' health and safety across our country,' said Skye Perryman, the president of Democracy Forward, which is representing the coalition of plaintiffs in the lawsuit. The lawsuit does not challenge the Trump administration's restriction on immigrants signing up for the coverage. The Biden administration saw gains in Obamacare enrollment as a major success of the Democratic president's term, noting that a record 24 million people signed up for the coverage, thanks to generous tax breaks offered through the 2022 Inflation Reduction Act. But the program has been a target of Trump, who has said it is riddled with problems that make the coverage unaffordable for many without large subsidies. Enrollment in the program dipped during his first term in office.
